Form 8-K - Current report:
SEC Accession No. 0001013762-25-001309
Filing Date
2025-03-24
Accepted
2025-03-24 10:27:40
Documents
15
Period of Report
2025-03-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0234771-8k_inmune.htm   iXBRL 8-K 23080
2 PRESS RELEASE DATED MARCH 24, 2025 ea023477102ex99-1_inmune.htm EX-99.1 10944
3 GRAPHIC ex99-1_001.jpg GRAPHIC 1870
  Complete submission text file 0001013762-25-001309.txt   213052

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inmb-20250324.xsd EX-101.SCH 3018
5 XBRL LABEL FILE inmb-20250324_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE inmb-20250324_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0234771-8k_inmune_htm.xml XML 3679
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 25762768
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)